Cargando…

Weekly adalimumab treatment decreased disease flare in hidradenitis suppurativa over 36 weeks: integrated results from the phase 3 PIONEER trials

BACKGROUND: Hidradenitis suppurativa (HS) is a chronic skin disease characterized by inflammatory lesions that flare unpredictably. The impact of weekly adalimumab (ADAew) on HS flare is not well‐characterized. OBJECTIVE: To evaluate the impact of disease flare on health‐related quality of life (HRQ...

Descripción completa

Detalles Bibliográficos
Autores principales:	van der Zee, H.H., Longcore, M., Geng, Z., Garg, A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Acne, Rosacea and Hidradenitis Suppurativa
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7318582/ https://www.ncbi.nlm.nih.gov/pubmed/31630445 http://dx.doi.org/10.1111/jdv.16023

Ejemplares similares

Improvement in Hidradenitis Suppurativa and quality of life in patients treated with adalimumab: Real‐world results from the HARMONY Study
por: Hafner, A., et al.
Publicado: (2021)

Real‐world effectiveness of adalimumab in patients with moderate‐to‐severe hidradenitis suppurativa: the 1‐year SOLACE study
por: Gulliver, W., et al.
Publicado: (2021)

Primary alterations during the development of hidradenitis suppurativa
por: Dajnoki, Z., et al.
Publicado: (2021)

A novel nicastrin mutation in a three‐generation Dutch family with hidradenitis suppurativa: a search for functional significance
por: Vossen, A.R.J.V., et al.
Publicado: (2020)

Creation of a severity index for hidradenitis suppurativa that includes a validated quality‐of‐life measure: the HIDRAscore
por: Marzano, A.V., et al.
Publicado: (2020)

Baseline patient‐reported outcomes from UNITE: an observational, international, multicentre registry to evaluate hidradenitis suppurativa in clinical practice
por: Kimball, A.B., et al.
Publicado: (2020)

Surgical outcomes and the impact of major surgery on quality of life, activity impairment and sexual health in hidradenitis suppurativa patients: a prospective single centre study
por: Prens, L.M., et al.
Publicado: (2019)

Apremilast for moderate hidradenitis suppurativa: no significant change in lesional skin inflammatory biomarkers
por: Vossen, A.R.J.V., et al.
Publicado: (2018)

Long‐term safety and efficacy of trifarotene 50 μg/g cream, a first‐in‐class RAR‐γ selective topical retinoid, in patients with moderate facial and truncal acne
por: Blume‐Peytavi, U., et al.
Publicado: (2019)

HIDRAdisk: validation of an innovative visual tool to assess the burden of hidradenitis suppurativa
por: Peris, K., et al.
Publicado: (2019)

Papulopustular rosacea and rosacea‐like demodicosis: two phenotypes of the same disease?
por: Forton, F.M.N., et al.
Publicado: (2018)

The influence of exposome on acne
por: Dréno, B., et al.
Publicado: (2018)

Acne relapses: impact on quality of life and productivity
por: Dreno, B., et al.
Publicado: (2019)

Consensus on the treatment of hidradenitis suppurativa - Brazilian Society of Dermatology
por: Magalhães, Renata Ferreira, et al.
Publicado: (2019)

New treatments and new assessment instruments for Hidradenitis suppurativa
por: van Straalen, Kelsey R., et al.
Publicado: (2022)

Safety of Adalimumab Dosed Every Week and Every Other Week: Focus on Patients with Hidradenitis Suppurativa or Psoriasis
por: Ryan, Caitriona, et al.
Publicado: (2018)

Characterizing perimenstrual flares of hidradenitis suppurativa
por: Collier, Erin K., et al.
Publicado: (2020)

Successful Treatment of Recalcitrant Hidradenitis Suppurativa with Adalimumab
por: Gorovoy, Ian, et al.
Publicado: (2009)

Hidradenitis suppurativa and adalimumab in the COVID-19 era
por: Marzano, Angelo Valerio, et al.
Publicado: (2021)

Two Cases of Paradoxical Hidradenitis Suppurativa while on Adalimumab
por: Harvin, Glenn, et al.
Publicado: (2016)

Treatment of Hidradenitis Suppurativa Patient with Klinefelter Syndrome by Adalimumab
por: Shin, Ji Yeoun, et al.
Publicado: (2019)

Adalimumab-Induced Thrombocytopenia in a Patient With Hidradenitis Suppurativa
por: Al-Tkrit, Amna, et al.
Publicado: (2021)

ALK+ ALCL in the setting of adalimumab‐related hidradenitis suppurativa
por: Craig, Alexander, et al.
Publicado: (2023)

Real‐world safety and effectiveness of adalimumab in patients with hidradenitis suppurativa: 12‐week interim analysis of post‐marketing surveillance in Japan
por: Hayashi, Nobukazu, et al.
Publicado: (2022)

Management of mild hidradenitis suppurativa: our greatest challenge yet
por: van der Zee, H.H., et al.
Publicado: (2021)

Spotlight on adalimumab in the treatment of active moderate-to-severe hidradenitis suppurativa
por: Fotiadou, Christina, et al.
Publicado: (2016)

Genital lymphedema associated with hidradenitis suppurativa unresponsive to adalimumab treatment
por: Musumeci, Maria Letizia, et al.
Publicado: (2019)

A complication in a patient with hidradenitis suppurativa taking adalimumab
por: Perez, Olivia D., et al.
Publicado: (2022)

Optic neuropathy in a patient treated with adalimumab for hidradenitis suppurativa
por: Alnaif, Sarah, et al.
Publicado: (2023)

Guidelines for Qualifications of Neurodiagnostic Personnel: A Joint Position Statement of the American Clinical Neurophysiology Society, the American Association of Neuromuscular & Electrodiagnostic Medicine, the American Society of Neurophysiological Monitoring, and ASET—The Neurodiagnostic Society
por: López, Jaime R., et al.
Publicado: (2023)

Cura tu acné : dietas y nuevos tratamientos
por: Hoehn, Gustave H.
Publicado: (1997)

Adalimumab medium‐term dosing strategy in moderate‐to‐severe hidradenitis suppurativa: integrated results from the phase III randomized placebo‐controlled PIONEER trials
por: Jemec, G.B.E., et al.
Publicado: (2019)

Improvement of overlapping hidradenitis suppurativa and ankylosing spondylitis after the introduction of adalimumab
por: Bosnić, Dubravka, et al.
Publicado: (2016)

Efficacy of adalimumab in moderate to severe hidradenitis suppurativa: Real life data
por: Kyriakou, Aikaterini, et al.
Publicado: (2018)

The Impact of Body Mass Index Upon the Efficacy of Adalimumab in Hidradenitis Suppurativa
por: Frew, John W., et al.
Publicado: (2021)

Paradoxical Reaction in a Patient with Hidradenitis Suppurativa Undergoing Adalimumab Treatment
por: IKEYA, Soichiro, et al.
Publicado: (2021)

Real-world drug survival of patients with hidradenitis suppurativa treated with adalimumab
por: Saal, Ryan C., et al.
Publicado: (2023)

Damage in hidradenitis suppurativa: receiving the deserved attention
por: Aarts, Pim, et al.
Publicado: (2022)

Twenty‐four‐week interim analysis from a phase 3 open‐label trial of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa
por: Morita, Akimichi, et al.
Publicado: (2019)

Hidradenitis suppurativa flares following COVID-19 vaccination: A case series
por: Martora, Fabrizio, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mtu0mg8adscjbpk1h0ncjtdqhf